Farr M, Kitas G D, Waterhouse L, Jubb R, Felix-Davies D, Bacon P A
Department of Rheumatology, University of Birmingham, Medical School, UK.
Clin Rheumatol. 1988 Sep;7(3):372-7. doi: 10.1007/BF02239195.
Sulphasalazine (SASP) has recently become established as an effective treatment for active rheumatoid arthritis (RA), but has not previously been used in psoriatic arthritis in which remission-inducing drugs have proved disappointing. In this one year open study, 34 patients with active psoriatic arthritis were treated with sulphasalazine. An overall favourable clinical response was observed in 23 patients (67%). Nine patients (26%) achieved a very good therapeutic response and these either had arthritis associated with spondylitis or the symmetrical type of joint disease. Evaluation at 3, 6 and 12 months showed a significant improvement in inflammatory indices including a reduction in the C-reactive protein level and ESR. The drug was well-tolerated and side-effects were mild. Eight patients (23.5%) stopped the drug because of reactions and one patient with a rash was successfully desensitised. Fifty-three percent continued the drug into the second year. No apparent exacerbation of the psoriasis was observed. These results suggest that sulphasalazine is a safe and potentially effective drug in the treatment of psoriatic arthritis. A double-blind placebo-controlled trial has been set up to determine its true efficacy.
柳氮磺胺吡啶（SASP）最近已被确认为治疗活动性类风湿性关节炎（RA）的有效药物，但此前尚未用于治疗银屑病关节炎，因为事实证明能诱导缓解的药物令人失望。在这项为期一年的开放性研究中，34例活动性银屑病关节炎患者接受了柳氮磺胺吡啶治疗。23例患者（67%）观察到总体良好的临床反应。9例患者（26%）获得了非常好的治疗反应，这些患者要么患有与脊柱炎相关的关节炎，要么患有对称性关节疾病。在3个月、6个月和12个月时的评估显示，炎症指标有显著改善，包括C反应蛋白水平和血沉降低。该药物耐受性良好，副作用轻微。8例患者（23.5%）因不良反应停药，1例皮疹患者成功脱敏。53%的患者持续用药至第二年。未观察到银屑病明显加重。这些结果表明，柳氮磺胺吡啶是治疗银屑病关节炎的一种安全且可能有效的药物。已开展一项双盲安慰剂对照试验以确定其真正疗效。
